Bladder cancer: a new combo aims to avoid radical surgery

NCT ID NCT07756008

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether combining two drugs—disitamab vedotin and toripalimab—with or without pelvic lymph node removal can help people with muscle-invasive bladder cancer keep their bladder. Participants, who have HER2-positive tumors and decline bladder removal surgery, will receive a procedure to remove the tumor followed by the drug combo. The study compares outcomes between those who also have lymph nodes removed and those who don't, focusing on survival without bladder cancer returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
disitamab vedotin (an antibody-drug conjugate) combined with toripalimab (an immunotherapy drug), plus a procedure to remove bladder tumors and, in some patients, pelvic lymph nodes
What this could lead to
If successful, this approach could offer a way to treat muscle-invasive bladder cancer without removing the bladder, potentially preserving quality of life while controlling the disease.
What could go wrong
This is an early-phase trial, so the combination may not work as hoped or could cause significant side effects. The benefit of adding lymph node removal is uncertain and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, 300211, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.